The impact of counterfeit drugs in south and south-east Asia
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
List view / Grid view
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
The MHRA has given marketing authorisation for short-term jet-lag therapy in adults.
The government has issued a letter to the pharmaceutical industry, outlining how to prepare for a no-deal Brexit.
Whether by ignorance of the latest best practices, or willful disregard for patient safety, the results of careless practice can often be fatal. The articles in this in-depth focus highlight how regulatory bodies are taking action to raise the industry’s game.
The FDA has announced its approval of a therapy for hypoactive sexual desire disorder in premenopausal women.
DHL Supply Chain is investing millions of dollars to expand its pharmaceutical and medical device distribution network in the US.
A multi-company system to improve traceability of pharmaceutical products is newly supported by the FDA.
In this issue we explore reasons behind critical key drug shortages in the EU, whether viability methods effectively detect all viable organisms and how companies can future-proof their digital technologies ahead of Brexit. Also included are articles on higher order protein structure, FMD compliance and Raman spectroscopy.
A data analyst has reported that the current US-China trade war will give India chance to increase their pharmaceutical presence.
Emirates SkyCargo has commenced handling pharmaceutical cargo at a new purpose-built facility in Chicago.
Decreased supply of anti-rabies vaccines (ARVs) in Delhi causes outbreak of the disease.
Walmart has joined a consortium that’s attempting to build a blockchain for tracking pharmaceutical supply chains.
Global active pharmaceutical ingredients market set to surpass US$274.9 billion by 2026.
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
With the UK bracing itself for a 'no-deal' Brexit or some other outcome that has not yet been determined, pharma experts discussed the potential effect of Brexit on the supply chain and how to best prepare for it against the upcoming deadline.